Drug manufacturers are beginning to explore new contract models to support industrywide calls for value-based-care reform.
New trends in value-based pharmaceutical contracting are emerging. Win-win negotiations require the right drug, the right outcome, and the right data sharing agreement.
Cardiology, infectious disease, and oncology are the leading high-impact areas where health insurers are finding success.